Shots:
- AstraZeneca has reported P-III (PREVAIL) trial assessing gefurulimab vs PBO in 260 gMG adults for 26wks. across North America, EU, & APAC region; eligible pts could then enter an ongoing OLE study
- Trial met its 1EP & all 2EPs, showing significant improvement in MG-ADL total score from baseline at 26wks. in adults with AChR antibody-positive gMG; data to be presented in future conference & shared with global health authorities
- Gefurulimab, a dual-binding nanobody & C5 inhibitor, is designed for SC self-administration & acts by blocking the terminal complement cascade to prevent immune-mediated damage to healthy cells
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News:- AstraZeneca Reports P-III (FLAURA2) Trial Findings on Tagrisso Regimen to Treat EGFRm NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
